NASDAQ:IOVA - Iovance Biotherapeutics Stock Price, Forecast & News

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its quarterly earnings data on Monday, November, 4th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by $0.01. View Iovance Biotherapeutics' Earnings History.

Iovance Biotherapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, February 26th 2020. View Earnings Estimates for Iovance Biotherapeutics.

12 analysts have issued 12-month price targets for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $38.00. On average, they anticipate Iovance Biotherapeutics' share price to reach $31.73 in the next twelve months. This suggests a possible upside of 44.1% from the stock's current price. View Analyst Price Targets for Iovance Biotherapeutics.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iovance Biotherapeutics.

News articles about IOVA stock have been trending negative on Wednesday, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a news sentiment score of -2.1 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 3.0 out of 10, indicating that recent press coverage is unlikely to have an effect on the company's share price in the near future. View News Stories for Iovance Biotherapeutics.

Iovance Biotherapeutics saw a decline in short interest in January. As of January 15th, there was short interest totalling 14,830,000 shares, a decline of 9.5% from the December 31st total of 16,390,000 shares. Based on an average daily trading volume, of 1,270,000 shares, the short-interest ratio is currently 11.7 days. Approximately 12.8% of the shares of the stock are sold short. View Iovance Biotherapeutics' Current Options Chain.

Some companies that are related to Iovance Biotherapeutics include Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), BioNTech (BNTX), Qiagen (QGEN), Moderna (MRNA), argenx (ARGX), Repligen (RGEN), bluebird bio (BLUE), China Biologic Products (CBPO), Spark Therapeutics (ONCE), Ablynx (ABLYF), Adaptive Biotechnologies (ADPT), Crispr Therapeutics (CRSP), Allogene Therapeutics (ALLO) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Portola Pharmaceuticals (PTLA), Applied Materials (AMAT), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Novavax (NVAX) and Heron Therapeutics (HRTX).

Iovance Biotherapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.43%), Rhenman & Partners Asset Management AB (0.38%), California Public Employees Retirement System (0.25%), Strs Ohio (0.10%), Moody Lynn & Lieberson LLC (0.06%) and Tocqueville Asset Management L.P. (0.05%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Institutional Ownership Trends for Iovance Biotherapeutics.

IOVA stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Tocqueville Asset Management L.P., Rhenman & Partners Asset Management AB, Evanson Asset Management LLC and Zurcher Kantonalbank Zurich Cantonalbank . View Insider Buying and Selling for Iovance Biotherapeutics.

IOVA stock was purchased by a variety of institutional investors in the last quarter, including Moody Lynn & Lieberson LLC, Dupont Capital Management Corp, Virginia Retirement Systems ET AL, California Public Employees Retirement System, Intellectus Partners LLC, Strs Ohio and SG Americas Securities LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View Insider Buying and Selling for Iovance Biotherapeutics.

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IOVA stock can currently be purchased for approximately $22.01.

Iovance Biotherapeutics has a market capitalization of $2.78 billion. The biotechnology company earns $-123,580,000.00 in net income (profit) each year or ($1.27) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.View Additional Information About Iovance Biotherapeutics.

The official website for Iovance Biotherapeutics is http://www.iovance.com/.

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]